Daniel S. Lorrain, who serves as the Chief Scientific Officer at Contineum Therapeutics, Inc. (NASDAQ: CTNM), executed a series of stock transactions totaling approximately $594,578 on June 30 and July 1, 2026. These sales were carried out under a pre-arranged 10b5-1 trading plan that Mr. Lorrain adopted on September 23, 2025. The transactions were executed at weighted average prices ranging from $15.6667 to $16.2369 per share. The insider sales come as Contineum's stock trades near its 52-week high of $16.91, having delivered a remarkable 277.5% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, placing it among companies on the most overvalued list. The shares have gained over 13% in the past week alone, with the company's market capitalization standing at $569.77 million.
On June 30, Mr. Lorrain acquired 28,826 shares of Class A Common Stock by exercising stock options at a price of $1.01 per share. These options were fully vested and exercisable. Immediately following this acquisition, he sold all 28,826 shares at a weighted average price of $16.0372 per share. The shares sold on this date fetched prices between $16.00 and $16.35.
Further transactions occurred on July 1, when Mr. Lorrain acquired an additional 4,183 shares of Class A Common Stock through option exercises at $1.01 per share, also from fully vested and exercisable options. He then sold 5,852 shares at a weighted average price of $15.6667 per share, with individual sales prices ranging from $15.15 to $16.14. On the same day, he sold another 2,501 shares at a weighted average price of $16.2369 per share, with prices for these shares ranging from $16.16 to $16.40.
In total, Mr. Lorrain acquired 33,009 shares through option exercises for a total value of $33,339, and sold 37,179 shares for a total value of $594,578 during the reporting period.
Wall Street sentiment remains positive, with seven analysts recently revising their earnings estimates upward for the upcoming period. Analyst price targets range from $16 to $28 per share. InvestingPro subscribers have access to 11 additional exclusive tips about CTNM, along with comprehensive financial health metrics showing a "GOOD" overall score.
Following these transactions, Mr. Lorrain directly holds 135,202 shares of Contineum Therapeutics Class A Common Stock. Additionally, his spouse holds 10,110 shares indirectly, which includes 6,537 shares acquired through the company's Employee Stock Purchase Plan.
In other recent news, Contineum Therapeutics, Inc. has announced the publication of a manuscript detailing the discovery and characterization of its drug candidate PIPE-791. This lysophosphatidic acid receptor 1 (LPAR1) antagonist is designed to treat fibrotic conditions and features a chemical structure that allows for slow on-off binding rates and sustained target coverage. Additionally, Contineum reported topline data from a phase 1b trial of PIPE-791, which is being developed as an oral treatment for chronic osteoarthritis pain and chronic low back pain. The randomized, double-blind, placebo-controlled trial involved 43 patients and tested the drug at a dosage of 10mg once daily over a four-week crossover period. These developments reflect Contineum's ongoing efforts in advancing PIPE-791 through clinical trials.